Childhood Cancer Incidence, New York City, 2016-2020
Source: New York State Cancer Registry
| Site of Cancer | Ages 0-4 | Ages 5-9 | Ages 10-14 | Ages 15-19 | Combined Ages 0-14 | Combined Ages 0-19 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avg Annual Cases | Rate per 1,000,000 | Avg Annual Cases | Rate per 1,000,000 | Avg Annual Cases | Rate per 1,000,000 | Avg Annual Cases | Rate per 1,000,000 | Avg Annual Cases | Rate per 1,000,000 | 95% CI | Avg Annual Cases | Rate per 1,000,000 | 95% CI | |
| All Invasive Malignant Tumors | 129.2 | 241.5 | 69.8 | 143.8 | 87.2 | 194.2 | 131.6 | 296.7 | 286.2 | 192.3 | 182.4-202.5 | 417.8 | 218.5 | 209.2-228.1 |
| I Leukemias, myeloproliferative and myelodysplastic diseases | 42.2 | 78.9 | 20.6 | 42.4 | 20.6 | 45.9 | 24.4 | 55.0 | 83.4 | 55.4 | 50.2-61.1 | 107.8 | 55.3 | 50.7-60.2 |
| I(a) Lymphoid leukemias | 29.2 | 54.6 | 16.8 | 34.6 | 12.8 | 28.5 | 14.0 | 31.6 | 58.8 | 39.1 | 34.8-43.9 | 72.8 | 37.2 | 33.5-41.3 |
| I(b) Acute myeloid leukemia | 6.8 | 12.7 | 1.6 | 3.3 | 3.4 | 7.6 | 6.6 | 14.9 | 11.8 | 7.8 | 5.9-10.1 | 18.4 | 9.6 | 7.7-11.7 |
| II Lymphomas and reticuloendothelial neoplasms | 10.6 | 19.8 | 12.6 | 25.9 | 14.0 | 31.2 | 29.8 | 67.2 | 37.2 | 25.8 | 22.2-29.7 | 67.0 | 36.2 | 32.4-40.3 |
| II(a) Hodgkin lymphoma | 0.8 | 1.5 | 1.4 | 2.9 | 4.4 | 9.8 | 16.4 | 37.0 | 6.6 | 4.8 | 3.3-6.7 | 23.0 | 12.9 | 10.6-15.5 |
| II(b,c,d) Non-Hodgkin lymphomas | 9.6 | 17.9 | 11.2 | 23.1 | 9.6 | 21.4 | 13.0 | 29.3 | 30.4 | 20.8 | 17.6-24.4 | 43.4 | 23.0 | 20.0-26.2 |
| III CNS & misc intracranial & intraspinal neoplasms | 20.8 | 38.9 | 15.4 | 31.7 | 16.8 | 37.4 | 10.0 | 22.5 | 53.0 | 36.0 | 31.8-40.6 | 63.0 | 32.6 | 29.1-36.4 |
| III(a) Ependymomas and choroid plexus tumor | 2.6 | 4.9 | 0.4 | 0.8 | 0.6 | 1.3 | 0.6 | 1.4 | 3.6 | 2.3 | 1.4-3.7 | 4.2 | 2.1 | 1.3-3.2 |
| III(b) Astrocytoma | 8.4 | 15.7 | 7.6 | 15.7 | 8.2 | 18.3 | 4.6 | 10.4 | 24.2 | 16.6 | 13.7-19.8 | 28.8 | 15.0 | 12.7-17.7 |
| III(c) Intracranial and intraspinal embryonal tumors | 5.2 | 9.7 | 3.4 | 7.0 | 2.8 | 6.2 | 1.2 | 2.7 | 11.4 | 7.6 | 5.7-9.8 | 12.6 | 6.4 | 4.9-8.2 |
| III(d) Other gliomas | 3.4 | 6.4 | 3.2 | 6.6 | 4.6 | 10.2 | 2.8 | 6.3 | 11.2 | 7.8 | 5.9-10.1 | 14.0 | 7.4 | 5.8-9.4 |
| IV Neuroblastoma and other peripheral nervous cell tumors | 17.6 | 32.9 | 4.2 | 8.6 | 0.4 | 0.9 | 0.6 | 1.4 | 22.2 | 13.7 | 11.3-16.5 | 22.8 | 10.6 | 8.7-12.7 |
| IV(a) Neuroblastoma and ganglioneuroblastoma | 17.6 | 32.9 | 4.2 | 8.6 | 0.4 | 0.9 | 0.4 | 0.9 | 22.2 | 13.7 | 11.3-16.5 | 22.6 | 10.5 | 8.6-12.6 |
| V Retinoblastoma | 9.2 | 17.2 | 0.2 | 0.4 | 0.2 | 0.4 | 0.0 | 0.0 | 9.6 | 5.7 | 4.2-7.6 | 9.6 | 4.3 | 3.2-5.7 |
| VI Renal tumors | 10.0 | 18.7 | 2.0 | 4.1 | 1.4 | 3.1 | 1.0 | 2.3 | 13.4 | 8.5 | 6.6-10.8 | 14.4 | 6.9 | 5.4-8.7 |
| VI(a) Nephroblastoma and other nonepithelial renal tumor | 10.0 | 18.7 | 1.8 | 3.7 | 0.4 | 0.9 | 0.0 | 0.0 | 12.2 | 7.6 | 5.8-9.8 | 12.2 | 5.7 | 4.3-7.3 |
| VII Hepatic tumors | 3.8 | 7.1 | 0.2 | 0.4 | 0.4 | 0.9 | 1.0 | 2.3 | 4.4 | 2.7 | 1.7-4.1 | 5.4 | 2.6 | 1.7-3.8 |
| VII(a) Hepatoblastoma and mesenchymal tumors of liver | 3.8 | 7.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.5 | 3.8 | 2.3 | 1.4-3.6 | 4.0 | 1.8 | 1.1-2.8 |
| VIII Malignant bone tumors | 1.0 | 1.9 | 4.2 | 8.6 | 9.4 | 20.9 | 9.6 | 21.6 | 14.6 | 10.7 | 8.3-13.4 | 24.2 | 13.4 | 11.1-16.0 |
| VIII(a) Osteosarcoma | 0.0 | 0.0 | 2.0 | 4.1 | 6.2 | 13.8 | 5.4 | 12.2 | 8.2 | 6.1 | 4.4-8.2 | 13.6 | 7.6 | 5.9-9.6 |
| VIII(c) Ewing tumor and related sarcomas of bone | 0.4 | 0.7 | 1.6 | 3.3 | 2.0 | 4.5 | 3.2 | 7.2 | 4.0 | 2.9 | 1.8-4.4 | 7.2 | 4.0 | 2.8-5.5 |
| IX Soft tissue and other extraosseous sarcomas | 8.0 | 15.0 | 5.4 | 11.1 | 7.8 | 17.4 | 9.0 | 20.3 | 21.2 | 14.5 | 11.8-17.5 | 30.2 | 15.9 | 13.5-18.7 |
| IX(a) Rhabdomyosarcoma | 4.8 | 9.0 | 2.6 | 5.4 | 1.8 | 4.0 | 1.6 | 3.6 | 9.2 | 6.0 | 4.4-8.1 | 10.8 | 5.4 | 4.1-7.1 |
| X Germ cell & trophoblastic tumors & gonadal neoplasms | 3.8 | 7.1 | 2.4 | 4.9 | 5.0 | 11.1 | 12.0 | 27.1 | 11.2 | 7.7 | 5.8-10.0 | 23.2 | 12.6 | 10.4-15.1 |
| X(a) Intracranial and intraspinal germ cell tumor | 0.4 | 0.7 | 0.6 | 1.2 | 2.0 | 4.5 | 0.8 | 1.8 | 3.0 | 2.2 | 1.2-3.6 | 3.8 | 2.1 | 1.2-3.2 |
| X(c) Malignant gonadal germ cell tumor | 1.4 | 2.6 | 1.4 | 2.9 | 2.8 | 6.2 | 8.6 | 19.4 | 5.6 | 3.9 | 2.6-5.7 | 14.2 | 7.8 | 6.1-9.9 |
| XI Other malignant epithelial neoplasms and malignant melanomas | 1.4 | 2.6 | 2.2 | 4.5 | 10.8 | 24.1 | 33.8 | 76.2 | 14.4 | 10.5 | 8.2-13.2 | 48.2 | 27.0 | 23.7-30.7 |
| XI(b) Thyroid carcinoma | 0.4 | 0.7 | 1.0 | 2.1 | 4.8 | 10.7 | 19.4 | 43.7 | 6.2 | 4.6 | 3.1-6.5 | 25.6 | 14.4 | 12.0-17.1 |
| XI(d) Malignant melanoma | 0.4 | 0.7 | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 3.6 | 0.4 | 0.2 | 0.0-0.9 | 2.0 | 1.1 | 0.5-2.0 |
| XII Other and unspecified malignant neoplasms | 0.4 | 0.7 | 0.4 | 0.8 | 0.2 | 0.4 | 0.4 | 0.9 | 1.0 | 0.7 | 0.2-1.6 | 1.4 | 0.7 | 0.3-1.5 |
Notes
- Incidence data are provisional, November 2022.
- Rates are per 1,000,000 children. Rates for 0-14 and 0-19 year age intervals are age-adjusted within these intervals to the 2000 US standard population, with 95% confidence intervals.
- Rates based on fewer than 4 cases per year are unstable and should be used with caution.
- Non-Hodgkin lymphomas, Burkitt, and miscellaneous lymphomas are grouped together under II(b,c,d).
